The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
May 11, 2026
View Complete Issue         Table of Contents 2019 
Nipocalimab (Imaavy) for Myasthenia Gravis (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nipocalimab (Imaavy) for Myasthenia Gravis (online only)
May 11, 2026 (Issue: 1754)
The FDA has approved the neonatal Fc receptor (FcRn) blocker nipocalimab (Imaavy – Janssen) for IV treatment of generalized myasthenia gravis (gMG) in patients ≥12 years old with anti-acetylcholine receptor (AChR) or anti-muscle-specific...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nipocalimab (Imaavy) for Myasthenia Gravis (online only)
Article code: 1754g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.